Does the National Institute for Health and Clinical Excellence only appraise new pharmaceuticals?

International Journal of Technology Assessment in Health Care

Volumn 23, Issue 3, 2007, Pages 349-353

  Linden, Luan ^a   Vondeling, Hindrik ^b   Packer, Claire ^a   Cook, Alison ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Health technology; Health technology assessment; National Institute for Health and Clinical Excellence; NICE; Topic selection

Indexed keywords

CLINICAL EXCELLENCE; HEALTH TECHNOLOGY; NATIONAL INSTITUTE; NICE; TOPIC SELECTION;

BIOMEDICAL EQUIPMENT; CLINICAL LABORATORIES; DRUG PRODUCTS; HEALTH CARE; MEDICAL APPLICATIONS; SENSITIVITY ANALYSIS;

SOCIETIES AND INSTITUTIONS;

BIOMEDICAL TECHNOLOGY ASSESSMENT; DEVICE; HEALTH CARE ORGANIZATION; HEALTH SERVICE; REVIEW; SENSITIVITY ANALYSIS; UNITED KINGDOM;

EQUIPMENT AND SUPPLIES; HUMANS; NATIONAL INSTITUTES OF HEALTH (U.S.); ORGANIZATIONAL OBJECTIVES; PHARMACEUTICAL PREPARATIONS; TECHNOLOGY ASSESSMENT, BIOMEDICAL; UNITED STATES;

EID: 34250753214     PISSN: 02664623     EISSN: 14716348     Source Type: Journal    
DOI: 10.1017/S0266462307070468     Document Type: Review

References (14)

1. ABACUS International. Measuring the impact of NICE guidance across 28 disease areas. ABACUS International. 2005. Available at: http://www.abacusint.com/downloads/NICE_Guidance_Abacus_International.pdf. Accessed September 8, 2006.
2. Booth-Clibborn N, Packer C, Stevens A. Health technology diffusion rates: Statins, coronary stents and MRI in England. Int J Technol Assess Health Care. 2000;16:781-786.
3. Bosanquet N. NICE to see you... Health Serv J. 2003;(June):30-31.
4. Cook A, Packer C, Stevens A, et al. Influences upon the diffusion of thrombolysis for acute myocardial infarction in England: Case study. Int J Technol Assess Health Care. 2005;20:537-544.
5. Department of Health. National Institute for Health and Clinical Excellence. Selection of topics. A consultation paper. London: Department of Health. 2006. Available at: http://www.dh.gov.uk/assetRoot/04/13/10/56/ 04131056.pdf. Accessed June 30, 2006.
6. Department of Health. New statutory obligations for the NHS to fund treatments recommended by NICE. Press release: 2001/0599. London: Department of Health; 2001.
7. FDA. Approval times for priority and standard NME's: Calendar years 1993-2003. FDA. 2004. Available at: http://www.fda.gov/cder/rdmt/NMEapps93- 03.htm. Accessed June 30, 2006.
8. Maynard A, Bloor K, Freemantle N. Challenges for the National Institute for Clinical Excellence. BMJ. 2004;329:227-229.
9. NHS Executive. A first class service - Quality in the new NHS. London: Department of Health; 1998.
10. NHS Executive. "Faster access to modern treatment": How NICE appraisal will work. London: Department of Health; 1999.
11. Packer C, Stevens A, Cook A, et al. Diffusion of thrombolysis for acute myocardial infarction from 1981 to 2000 in England: Trend analysis and comparison with need. Int J Technol Assess Health Care. 2004;20:531-536.
12. Pirovano D. Threats, challenges and opportunities for the device industry in Europe. Clinica [1179], 5-6. London: T&F Informa UK Ltd; 2005.
13. Ryan J, Piercy J, James P. Assessment of NICE guidance on two surgical procedures. Lancet. 2004;363:1525-1526.
14. Towse A, Pritchard C. National Institute for Clinical Excellence (NICE): Is economic appraisal working? Pharmacoeconomics. 2002;20(Suppl 3):95-105.